Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant Recipients
In this study of 16 patients with chronic HCV genotype 1 infection who were undergoing liver transplantation from an HCV-negative donor, a 4-week course of once-daily ledipasvir–sofosbuvir achieved a sustained virologic response in 14 of the 15 patients who completed treatment. To the Editor: Hepati...
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2016-11, Vol.375 (21), p.2106-2108 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2108 |
|---|---|
| container_issue | 21 |
| container_start_page | 2106 |
| container_title | The New England journal of medicine |
| container_volume | 375 |
| creator | Levitsky, Josh Verna, Elizabeth C O’Leary, Jacqueline G Bzowej, Natalie H Moonka, Dilip K Hyland, Robert H Arterburn, Sarah Dvory-Sobol, Hadas Brainard, Diana M McHutchison, John G Terrault, Norah A |
| description | In this study of 16 patients with chronic HCV genotype 1 infection who were undergoing liver transplantation from an HCV-negative donor, a 4-week course of once-daily ledipasvir–sofosbuvir achieved a sustained virologic response in 14 of the 15 patients who completed treatment.
To the Editor:
Hepatitis C virus (HCV) infection continues to be the most frequent indication for liver transplantation, but recurrence of infection is nearly universal in patients who are viremic at the time of transplantation.
1
Direct-acting antiviral agents (DAAs) have been shown to be effective in treating recurrent HCV infection
2
,
3
but have not been tested in preventing reinfection at the time of liver transplantation. Because HCV RNA levels fall precipitously after liver transplantation owing to removal of the liver, the immediate perioperative period before rebound of viremia represents a unique opportunity to cure HCV infection.
4
We hypothesized that a . . . |
| doi_str_mv | 10.1056/NEJMc1611829 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1852671709</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>4261363551</sourcerecordid><originalsourceid>FETCH-LOGICAL-c386t-d0d3fa64030cb6ca44292848e319bf7c2ab6f975824e246d8b75e8cdd1ce51813</originalsourceid><addsrcrecordid>eNpt0MtKxDAUBuAgio6XnWsp6MKF1dyaJksZRkepF7xtS5qeQobpxaQV3PkOvqFPYmRGEfFsDgc-fg4_QrsEHxOciJPryeWVIYIQSdUKGpGEsZhzLFbRCGMqY54qtoE2vZ_hMISrdbRBU5WolCUjlN2Cs20HTvf2BaIMSttp_2Ldx9v7fVu1vhjCEVWti6bjp8g2URacix-cbnw3100f3YGxnYWm99tordJzDzvLvYUezyYP42mc3ZxfjE-z2DAp-rjEJau04JhhUwijOaeKSi6BEVVUqaG6EJVKE0k5UC5KWaQJSFOWxEBCJGFb6HCR27n2eQDf57X1BubhHWgHnxOZUJGSFKtA9__QWTu4JnwXFGeESilEUEcLZVzrvYMq75yttXvNCc6_Ws5_txz43jJ0KGoof_B3rQEcLEBd-7yBWf1_zifLE4KN</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1843128866</pqid></control><display><type>article</type><title>Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant Recipients</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Levitsky, Josh ; Verna, Elizabeth C ; O’Leary, Jacqueline G ; Bzowej, Natalie H ; Moonka, Dilip K ; Hyland, Robert H ; Arterburn, Sarah ; Dvory-Sobol, Hadas ; Brainard, Diana M ; McHutchison, John G ; Terrault, Norah A</creator><creatorcontrib>Levitsky, Josh ; Verna, Elizabeth C ; O’Leary, Jacqueline G ; Bzowej, Natalie H ; Moonka, Dilip K ; Hyland, Robert H ; Arterburn, Sarah ; Dvory-Sobol, Hadas ; Brainard, Diana M ; McHutchison, John G ; Terrault, Norah A</creatorcontrib><description>In this study of 16 patients with chronic HCV genotype 1 infection who were undergoing liver transplantation from an HCV-negative donor, a 4-week course of once-daily ledipasvir–sofosbuvir achieved a sustained virologic response in 14 of the 15 patients who completed treatment.
To the Editor:
Hepatitis C virus (HCV) infection continues to be the most frequent indication for liver transplantation, but recurrence of infection is nearly universal in patients who are viremic at the time of transplantation.
1
Direct-acting antiviral agents (DAAs) have been shown to be effective in treating recurrent HCV infection
2
,
3
but have not been tested in preventing reinfection at the time of liver transplantation. Because HCV RNA levels fall precipitously after liver transplantation owing to removal of the liver, the immediate perioperative period before rebound of viremia represents a unique opportunity to cure HCV infection.
4
We hypothesized that a . . .</description><identifier>ISSN: 0028-4793</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMc1611829</identifier><identifier>PMID: 27959735</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Antiviral Agents - therapeutic use ; Benzimidazoles - therapeutic use ; Chronic infection ; Fluorenes - therapeutic use ; Genotypes ; Hepacivirus - genetics ; Hepacivirus - isolation & purification ; Hepatitis C, Chronic - drug therapy ; Hepatitis C, Chronic - surgery ; Humans ; Infections ; Liver diseases ; Liver Transplantation ; Patients ; Perioperative Care ; RNA, Viral - blood ; Sofosbuvir - therapeutic use ; Transplants & implants</subject><ispartof>The New England journal of medicine, 2016-11, Vol.375 (21), p.2106-2108</ispartof><rights>Copyright © 2016 Massachusetts Medical Society. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c386t-d0d3fa64030cb6ca44292848e319bf7c2ab6f975824e246d8b75e8cdd1ce51813</citedby><cites>FETCH-LOGICAL-c386t-d0d3fa64030cb6ca44292848e319bf7c2ab6f975824e246d8b75e8cdd1ce51813</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMc1611829$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1843128866?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,776,780,2745,2746,26082,27903,27904,52361,54043,64362,64364,64366,72216</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27959735$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Levitsky, Josh</creatorcontrib><creatorcontrib>Verna, Elizabeth C</creatorcontrib><creatorcontrib>O’Leary, Jacqueline G</creatorcontrib><creatorcontrib>Bzowej, Natalie H</creatorcontrib><creatorcontrib>Moonka, Dilip K</creatorcontrib><creatorcontrib>Hyland, Robert H</creatorcontrib><creatorcontrib>Arterburn, Sarah</creatorcontrib><creatorcontrib>Dvory-Sobol, Hadas</creatorcontrib><creatorcontrib>Brainard, Diana M</creatorcontrib><creatorcontrib>McHutchison, John G</creatorcontrib><creatorcontrib>Terrault, Norah A</creatorcontrib><title>Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant Recipients</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>In this study of 16 patients with chronic HCV genotype 1 infection who were undergoing liver transplantation from an HCV-negative donor, a 4-week course of once-daily ledipasvir–sofosbuvir achieved a sustained virologic response in 14 of the 15 patients who completed treatment.
To the Editor:
Hepatitis C virus (HCV) infection continues to be the most frequent indication for liver transplantation, but recurrence of infection is nearly universal in patients who are viremic at the time of transplantation.
1
Direct-acting antiviral agents (DAAs) have been shown to be effective in treating recurrent HCV infection
2
,
3
but have not been tested in preventing reinfection at the time of liver transplantation. Because HCV RNA levels fall precipitously after liver transplantation owing to removal of the liver, the immediate perioperative period before rebound of viremia represents a unique opportunity to cure HCV infection.
4
We hypothesized that a . . .</description><subject>Antiviral Agents - therapeutic use</subject><subject>Benzimidazoles - therapeutic use</subject><subject>Chronic infection</subject><subject>Fluorenes - therapeutic use</subject><subject>Genotypes</subject><subject>Hepacivirus - genetics</subject><subject>Hepacivirus - isolation & purification</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Hepatitis C, Chronic - surgery</subject><subject>Humans</subject><subject>Infections</subject><subject>Liver diseases</subject><subject>Liver Transplantation</subject><subject>Patients</subject><subject>Perioperative Care</subject><subject>RNA, Viral - blood</subject><subject>Sofosbuvir - therapeutic use</subject><subject>Transplants & implants</subject><issn>0028-4793</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpt0MtKxDAUBuAgio6XnWsp6MKF1dyaJksZRkepF7xtS5qeQobpxaQV3PkOvqFPYmRGEfFsDgc-fg4_QrsEHxOciJPryeWVIYIQSdUKGpGEsZhzLFbRCGMqY54qtoE2vZ_hMISrdbRBU5WolCUjlN2Cs20HTvf2BaIMSttp_2Ldx9v7fVu1vhjCEVWti6bjp8g2URacix-cbnw3100f3YGxnYWm99tordJzDzvLvYUezyYP42mc3ZxfjE-z2DAp-rjEJau04JhhUwijOaeKSi6BEVVUqaG6EJVKE0k5UC5KWaQJSFOWxEBCJGFb6HCR27n2eQDf57X1BubhHWgHnxOZUJGSFKtA9__QWTu4JnwXFGeESilEUEcLZVzrvYMq75yttXvNCc6_Ws5_txz43jJ0KGoof_B3rQEcLEBd-7yBWf1_zifLE4KN</recordid><startdate>20161124</startdate><enddate>20161124</enddate><creator>Levitsky, Josh</creator><creator>Verna, Elizabeth C</creator><creator>O’Leary, Jacqueline G</creator><creator>Bzowej, Natalie H</creator><creator>Moonka, Dilip K</creator><creator>Hyland, Robert H</creator><creator>Arterburn, Sarah</creator><creator>Dvory-Sobol, Hadas</creator><creator>Brainard, Diana M</creator><creator>McHutchison, John G</creator><creator>Terrault, Norah A</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20161124</creationdate><title>Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant Recipients</title><author>Levitsky, Josh ; Verna, Elizabeth C ; O’Leary, Jacqueline G ; Bzowej, Natalie H ; Moonka, Dilip K ; Hyland, Robert H ; Arterburn, Sarah ; Dvory-Sobol, Hadas ; Brainard, Diana M ; McHutchison, John G ; Terrault, Norah A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c386t-d0d3fa64030cb6ca44292848e319bf7c2ab6f975824e246d8b75e8cdd1ce51813</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Benzimidazoles - therapeutic use</topic><topic>Chronic infection</topic><topic>Fluorenes - therapeutic use</topic><topic>Genotypes</topic><topic>Hepacivirus - genetics</topic><topic>Hepacivirus - isolation & purification</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Hepatitis C, Chronic - surgery</topic><topic>Humans</topic><topic>Infections</topic><topic>Liver diseases</topic><topic>Liver Transplantation</topic><topic>Patients</topic><topic>Perioperative Care</topic><topic>RNA, Viral - blood</topic><topic>Sofosbuvir - therapeutic use</topic><topic>Transplants & implants</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Levitsky, Josh</creatorcontrib><creatorcontrib>Verna, Elizabeth C</creatorcontrib><creatorcontrib>O’Leary, Jacqueline G</creatorcontrib><creatorcontrib>Bzowej, Natalie H</creatorcontrib><creatorcontrib>Moonka, Dilip K</creatorcontrib><creatorcontrib>Hyland, Robert H</creatorcontrib><creatorcontrib>Arterburn, Sarah</creatorcontrib><creatorcontrib>Dvory-Sobol, Hadas</creatorcontrib><creatorcontrib>Brainard, Diana M</creatorcontrib><creatorcontrib>McHutchison, John G</creatorcontrib><creatorcontrib>Terrault, Norah A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Proquest Nursing & Allied Health Source</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Levitsky, Josh</au><au>Verna, Elizabeth C</au><au>O’Leary, Jacqueline G</au><au>Bzowej, Natalie H</au><au>Moonka, Dilip K</au><au>Hyland, Robert H</au><au>Arterburn, Sarah</au><au>Dvory-Sobol, Hadas</au><au>Brainard, Diana M</au><au>McHutchison, John G</au><au>Terrault, Norah A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant Recipients</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2016-11-24</date><risdate>2016</risdate><volume>375</volume><issue>21</issue><spage>2106</spage><epage>2108</epage><pages>2106-2108</pages><issn>0028-4793</issn><eissn>1533-4406</eissn><abstract>In this study of 16 patients with chronic HCV genotype 1 infection who were undergoing liver transplantation from an HCV-negative donor, a 4-week course of once-daily ledipasvir–sofosbuvir achieved a sustained virologic response in 14 of the 15 patients who completed treatment.
To the Editor:
Hepatitis C virus (HCV) infection continues to be the most frequent indication for liver transplantation, but recurrence of infection is nearly universal in patients who are viremic at the time of transplantation.
1
Direct-acting antiviral agents (DAAs) have been shown to be effective in treating recurrent HCV infection
2
,
3
but have not been tested in preventing reinfection at the time of liver transplantation. Because HCV RNA levels fall precipitously after liver transplantation owing to removal of the liver, the immediate perioperative period before rebound of viremia represents a unique opportunity to cure HCV infection.
4
We hypothesized that a . . .</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>27959735</pmid><doi>10.1056/NEJMc1611829</doi><tpages>3</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2016-11, Vol.375 (21), p.2106-2108 |
| issn | 0028-4793 1533-4406 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1852671709 |
| source | MEDLINE; EZB-FREE-00999 freely available EZB journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Antiviral Agents - therapeutic use Benzimidazoles - therapeutic use Chronic infection Fluorenes - therapeutic use Genotypes Hepacivirus - genetics Hepacivirus - isolation & purification Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - surgery Humans Infections Liver diseases Liver Transplantation Patients Perioperative Care RNA, Viral - blood Sofosbuvir - therapeutic use Transplants & implants |
| title | Perioperative Ledipasvir–Sofosbuvir for HCV in Liver-Transplant Recipients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-22T09%3A12%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Perioperative%20Ledipasvir%E2%80%93Sofosbuvir%20for%20HCV%20in%20Liver-Transplant%20Recipients&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Levitsky,%20Josh&rft.date=2016-11-24&rft.volume=375&rft.issue=21&rft.spage=2106&rft.epage=2108&rft.pages=2106-2108&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMc1611829&rft_dat=%3Cproquest_cross%3E4261363551%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1843128866&rft_id=info:pmid/27959735&rfr_iscdi=true |